Cargando…

Discovery of novel CSF biomarkers to predict progression in dementia using machine learning

Providing an accurate prognosis for individual dementia patients remains a challenge since they greatly differ in rates of cognitive decline. In this study, we used machine learning techniques with the aim to identify cerebrospinal fluid (CSF) biomarkers that predict the rate of cognitive decline wi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gogishvili, Dea, Vromen, Eleonora M., Koppes-den Hertog, Sascha, Lemstra, Afina W., Pijnenburg, Yolande A. L., Visser, Pieter Jelle, Tijms, Betty M., Del Campo, Marta, Abeln, Sanne, Teunissen, Charlotte E., Vermunt, Lisa
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10121677/ https://www.ncbi.nlm.nih.gov/pubmed/37085545 http://dx.doi.org/10.1038/s41598-023-33045-x

Ejemplares similares

CSF proteomic signature predicts progression to Alzheimer's disease dementia
por: Vromen, Eleonora M., et al.
Publicado: (2022)

Biomarker A+T−: is this Alzheimer’s disease or not? A combined CSF and pathology study
por: Vromen, Eleonora M, et al.
Publicado: (2022)

Survival in memory clinic cohort is short, even in young-onset dementia
por: Rhodius-Meester, Hanneke Frederica Maria, et al.
Publicado: (2019)

Decision tree supports the interpretation of CSF biomarkers in Alzheimer's disease
por: Babapour Mofrad, Rosha, et al.
Publicado: (2018)

Alzheimer disease biomarkers may aid in the prognosis of MCI cases initially reverted to normal
por: Vermunt, Lisa, et al.
Publicado: (2019)

CSF proteome profiling reveals biomarkers to discriminate dementia with Lewy bodies from Alzheimer´s disease
por: del Campo, Marta, et al.
Publicado: (2023)

CSF proteomics in autosomal dominant Alzheimer’s disease highlights parallels with sporadic disease
por: van der Ende, Emma L, et al.
Publicado: (2023)

Amyloid-independent atrophy patterns predict time to progression to dementia in mild cognitive impairment
por: ten Kate, Mara, et al.
Publicado: (2017)

Unbiased estimates of cerebrospinal fluid β-amyloid 1–42 cutoffs in a large memory clinic population
por: Bertens, Daniela, et al.
Publicado: (2017)

Differential diagnostic performance of a panel of plasma biomarkers for different types of dementia
por: Thijssen, Elisabeth H., et al.
Publicado: (2022)

The effect of diagnostic criteria on outcome measures in preclinical and prodromal Alzheimer's disease: Implications for trial design
por: Bertens, Daniela, et al.
Publicado: (2017)

Neuroinflammatory CSF biomarkers MIF, sTREM1, and sTREM2 show dynamic expression profiles in Alzheimer’s disease
por: Hok-A-Hin, Yanaika S., et al.
Publicado: (2023)

Pre‐amyloid stage of Alzheimer's disease in cognitively normal individuals
por: Tijms, Betty M., et al.
Publicado: (2018)

Thimet oligopeptidase as a potential CSF biomarker for Alzheimer's disease: A cross‐platform validation study
por: Hok‐A‐Hin, Yanaika S., et al.
Publicado: (2023)

Novel CSF biomarkers to discriminate FTLD and its pathological subtypes
por: del Campo, Marta, et al.
Publicado: (2018)

Amyloid-β peptides in cerebrospinal fluid of patients with dementia with Lewy bodies
por: van Steenoven, Inger, et al.
Publicado: (2019)

Modeling grey matter atrophy as a function of time, aging or cognitive decline show different anatomical patterns in Alzheimer's disease
por: Dicks, Ellen, et al.
Publicado: (2019)

Music appreciation phenotypes in patients with frontotemporal dementia: A pilot study
por: van ‘t Hooft, Jochum J., et al.
Publicado: (2022)

How sticky are our proteins? Quantifying hydrophobicity of the human proteome
por: van Gils, Juami Hermine Mariama, et al.
Publicado: (2022)

Diagnostic Value of the CSF α-Synuclein Real-Time Quaking-Induced Conversion Assay at the Prodromal MCI Stage of Dementia With Lewy Bodies
por: Rossi, Marcello, et al.
Publicado: (2021)

Pathologically Decreased CSF Levels of Synaptic Marker NPTX2 in DLB Are Correlated with Levels of Alpha-Synuclein and VGF
por: Boiten, Walter A., et al.
Publicado: (2020)

New developments of biofluid‐based biomarkers for routine diagnosis and disease trajectories in frontotemporal dementia
por: del Campo, Marta, et al.
Publicado: (2022)

Clinical Phenotypes of Behavioral Variant Frontotemporal Dementia by Age at Onset
por: Fieldhouse, Jay L.P., et al.
Publicado: (2021)

Gray matter network properties show distinct associations with CSF p-tau 181 levels and amyloid status in individuals without dementia
por: Luigi, Lorenzini, et al.
Publicado: (2022)

CSF Proteomic Alzheimer’s Disease-Predictive Subtypes in Cognitively Intact Amyloid Negative Individuals
por: Tijms, Betty Marije, et al.
Publicado: (2021)

Abnormal cerebrospinal fluid levels of amyloid and tau are associated with cognitive decline over time in cognitively normal older adults: A monozygotic twin study
por: Tomassen, Jori, et al.
Publicado: (2022)

Prodromal Dementia With Lewy Bodies: Clinical Characterization and Predictors of Progression
por: van de Beek, Marleen, et al.
Publicado: (2020)

Grey matter network markers identify individuals with prodromal Alzheimer’s disease who will show rapid clinical decline
por: Pelkmans, Wiesje, et al.
Publicado: (2022)

Correction: Boiten et al. Pathologically Decreased CSF Levels of Synaptic Marker NPTX2 in DLB Are Correlated with Levels of Alpha-Synuclein and VGF. Cells 2021, 10, 38
por: Boiten, Walter A., et al.
Publicado: (2022)

Urine as matrix for analysis of neurofilament light chain is not suitable to distinguish frontotemporal dementia from psychiatric diseases
por: van Engelen, Marie-Paule E, et al.
Publicado: (2023)

Methods to Discover and Validate Biofluid-Based Biomarkers in Neurodegenerative Dementias
por: Teunissen, Charlotte E., et al.
Publicado: (2023)

Effects of age, amyloid, sex, and APOE ε4 on the CSF proteome in normal cognition
por: Wesenhagen, Kirsten E.J., et al.
Publicado: (2022)

Discriminative and prognostic potential of cerebrospinal fluid phosphoTau/tau ratio and neurofilaments for frontotemporal dementia subtypes
por: Pijnenburg, Yolande A.L., et al.
Publicado: (2015)

Novel CSF biomarkers in genetic frontotemporal dementia identified by proteomics
por: van der Ende, Emma L., et al.
Publicado: (2019)

Evaluation of the Digital Alzheimer Center: Testing Usability and Usefulness of an Online Portal for Patients with Dementia and Their Carers
por: Hattink, Bart, et al.
Publicado: (2016)

Variability of CSF Alzheimer’s Disease Biomarkers: Implications for Clinical Practice
por: Vos, Stephanie J. B., et al.
Publicado: (2014)

P-tau subgroups in AD relate to distinct amyloid production and synaptic integrity profiles
por: Wesenhagen, Kirsten E. J., et al.
Publicado: (2022)

Concatenating plasma p-tau to Alzheimer’s disease
por: Tijms, Betty M, et al.
Publicado: (2021)

Clusters of co-abundant proteins in the brain cortex associated with fronto-temporal lobar degeneration
por: Bridel, Claire, et al.
Publicado: (2023)

Disease-related determinants are associated with mortality in dementia due to Alzheimer’s disease
por: Rhodius-Meester, Hanneke F. M., et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_sbshikbnj3hi5c49nmsdhiu53c